Directors are buying these high growth stocks – should you follow them?

Edward Sheldon looks at two stocks that have seen sizeable director’s purchases in September.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Directors’ buys can be a useful indicator of the future prospects of a company. The theory goes that those with an inside knowledge of a company are unlikely to spend their hard earned cash on its shares if they don’t believe the company has a bright future ahead of it. Directors purchasing stock sends a signal to the market that those with the most knowledge of the business believe its share price will appreciate over time.

With that in mind, here’s a look at two fast growing companies in which directors have recently been buying shares.

Telit Communications

With the exception of the finance director, it’s unlikely many will have a deeper knowledge of a company than the chief executive. That’s why it’s worth noting that the CEO of Telit Communications (LSE: TCM), Oozi Cats, spent nearly £230,000 on Telit shares in September, taking his holding to just north of 20%. The director clearly has confidence in Telit, so does this mean it’s time to buy?

Personally, I believe Telit looks to be trading at an appealing level right now.

The company operates in the fast growing Internet of Things space, has grown its revenues from $207m to $333m over the last three years and has generated five-year total annualised shareholder returns of a huge 32% per annum. And after a sizeable correction in the share price of late, Telit can now be bought for a low multiple of 11 times FY2016 earnings, if analysts’ forecasts of 25c earnings per share are accurate.

Recent results for the half year ended 30 June saw revenue growth of 6.3%. And while adjusted profit before tax was lower than last year on the back of continued R&D efforts and setbacks in the ramp-up of certain products in the US, it’s expected that the company should benefit from typically strong seasonality in the second half of the year.

While a director putting his money on the line is no guarantee of future performance, at the current share price I believe Telit offers an attractive risk/reward skew.

Hikma Pharmaceuticals

The only thing better than one director purchasing shares in a company is multiple directors loading up and this is exactly what has happened at Hikma Pharmaceuticals (LSE: HIK) recently.

Three directors, including chairman and chief executive Said Darwazah, vice-chairman Mazen Darwazah and non-executive Ali Al-Hursy spent over £12m on Hikma stock in September, taking the opportunity to build a dominant stake in the company as the share price has slumped. 

Hikma’s share price has fallen dramatically since trading at around 2,700p in early August, after comments from US presidential candidate Hillary Clinton about the escalating cost of drugs has sent the sector lower and Hikma reported a drop in operating profits in its half-year results.

However Hikma is viewing 2016 as a “transitional year” after a string of significant acquisitions in the last few years and has stated that the company is “building a strong pipeline to support future growth.”

Earnings may be volatile in the short term while Hikma integrates its recent acquisitions, but with the share price falling 25% in two months and the company now trading on a P/E ratio of 17, for those willing to ride out the short-term earnings weakness, I believe it could be worth following in the directors’ footsteps and building a position in Hikma.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »